Update README.md
Browse files
README.md
CHANGED
|
@@ -1,23 +1,137 @@
|
|
| 1 |
---
|
| 2 |
license: apache-2.0
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| 3 |
---
|
| 4 |
-
---
|
| 5 |
-
license: apache-2.0
|
| 6 |
-
---
|
| 7 |
|
| 8 |
-
# MolScreen
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| 9 |
|
| 10 |
-
|
| 11 |
|
| 12 |
-
|
| 13 |
-
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| 14 |
|
| 15 |
-
|
| 16 |
-
**GitHub:** https://github.com/vgoradia/mol-screen
|
| 17 |
|
| 18 |
-
|
| 19 |
|
| 20 |
-
|
| 21 |
|
| 22 |
-
|
| 23 |
-
model.load_state_dict(torch.load('molscreen_best.pt'))
|
|
|
|
| 1 |
---
|
| 2 |
license: apache-2.0
|
| 3 |
+
tags:
|
| 4 |
+
- molecular-toxicity
|
| 5 |
+
- drug-discovery
|
| 6 |
+
- graph-neural-network
|
| 7 |
+
- cheminformatics
|
| 8 |
+
- tox21
|
| 9 |
+
- interpretability
|
| 10 |
+
- gineconv
|
| 11 |
+
language:
|
| 12 |
+
- en
|
| 13 |
---
|
|
|
|
|
|
|
|
|
|
| 14 |
|
| 15 |
+
# MolScreen: GNN for Molecular Toxicity Screening
|
| 16 |
+
|
| 17 |
+
**MolScreen** is a Graph Isomorphism Network with Edge features (GINEConv) trained on the Tox21 dataset for multi-task molecular toxicity prediction. It combines GNN-based predictions with gradient-based atom attribution and LLM-generated triage notes to make toxicity screening interpretable and actionable.
|
| 18 |
+
|
| 19 |
+
Developed by Veer Goradia. Accepted to **NeurIPS 2026 AIDaR Workshop** (Paris, December 2026).
|
| 20 |
+
|
| 21 |
+
## Model Description
|
| 22 |
+
|
| 23 |
+
Drug toxicity is one of the leading causes of late-stage clinical trial failure, costing billions in wasted development. MolScreen addresses two key gaps in existing approaches: most models give a probability but no explanation, and none integrate a human-readable summary for non-expert decision makers.
|
| 24 |
+
|
| 25 |
+
**Architecture:**
|
| 26 |
+
- GINEConv backbone — uses edge features (bond type, aromaticity, conjugation) that plain GCN/GIN discard
|
| 27 |
+
- Multi-task classification across 12 Tox21 endpoints simultaneously
|
| 28 |
+
- Masked BCE loss for Tox21's missing labels (5,800–7,200 valid labels per task)
|
| 29 |
+
- Gradient-based atom attribution: highlights which molecular substructures drove the prediction
|
| 30 |
+
- LLM triage layer: generates a 3-sentence actionable summary (SMILES + flagged probabilities + top-3 attributed atoms per task)
|
| 31 |
+
|
| 32 |
+
**Total parameters:** ~374,000
|
| 33 |
+
**Inference time:** ~0.7 seconds end-to-end (excluding LLM API call)
|
| 34 |
+
**Training time:** ~6 minutes on laptop CPU (60 epochs)
|
| 35 |
+
|
| 36 |
+
## Performance
|
| 37 |
+
|
| 38 |
+
### Random Split (10-seed validation)
|
| 39 |
+
| Metric | Value |
|
| 40 |
+
|--------|-------|
|
| 41 |
+
| Mean ROC-AUC | 0.8442 ± 0.0073 |
|
| 42 |
+
|
| 43 |
+
### Scaffold Split (10-seed validation)
|
| 44 |
+
| Metric | Value |
|
| 45 |
+
|--------|-------|
|
| 46 |
+
| Mean ROC-AUC | 0.7716 ± 0.0036 |
|
| 47 |
+
|
| 48 |
+
### Baseline Comparison (Scaffold Split)
|
| 49 |
+
| Model | ROC-AUC |
|
| 50 |
+
|-------|---------|
|
| 51 |
+
| **MolScreen (GINEConv)** | **0.7716** |
|
| 52 |
+
| Plain GCN | 0.7481 |
|
| 53 |
+
| Random Forest (Morgan FP) | 0.7465 |
|
| 54 |
+
| XGBoost (Morgan FP) | 0.7378 |
|
| 55 |
+
| Plain GIN | 0.7249 |
|
| 56 |
+
| Chen et al. SSL-GCN (2021) | 0.7570 |
|
| 57 |
+
|
| 58 |
+
MolScreen beats the best non-pretrained baseline (GCN) by 2.4 points. The GINEConv edge-awareness advantage over plain GIN (+4.7 points) confirms that bond-level features matter for generalization.
|
| 59 |
+
|
| 60 |
+
### Per-Task ROC-AUC (Random Split, representative run)
|
| 61 |
+
| Endpoint | AUC |
|
| 62 |
+
|----------|-----|
|
| 63 |
+
| NR-AR | 0.8518 |
|
| 64 |
+
| NR-AR-LBD | 0.9119 |
|
| 65 |
+
| NR-AhR | 0.8938 |
|
| 66 |
+
| NR-Aromatase | 0.8788 |
|
| 67 |
+
| NR-ER | 0.7486 |
|
| 68 |
+
| NR-ER-LBD | 0.8400 |
|
| 69 |
+
| NR-PPAR-gamma | 0.8918 |
|
| 70 |
+
| SR-ARE | 0.8125 |
|
| 71 |
+
| SR-ATAD5 | 0.8762 |
|
| 72 |
+
| SR-HSE | 0.7374 |
|
| 73 |
+
| SR-MMP | 0.9156 |
|
| 74 |
+
| SR-p53 | 0.8713 |
|
| 75 |
+
|
| 76 |
+
## Training Data
|
| 77 |
+
|
| 78 |
+
- **Dataset:** Tox21 (7,823 valid compounds, 12 toxicity endpoints)
|
| 79 |
+
- **Assay categories:** Nuclear receptor panel (NR-*) and stress response panel (SR-*)
|
| 80 |
+
- **Class imbalance:** 2.6%–16% positive rate per task
|
| 81 |
+
- **Splits:** Random split (80/10/10) and scaffold split (chemotype-based, harder generalization test)
|
| 82 |
+
|
| 83 |
+
## Intended Use
|
| 84 |
+
|
| 85 |
+
- Early-stage drug candidate toxicity screening
|
| 86 |
+
- Prioritizing which compounds advance to lab testing
|
| 87 |
+
- Interpretability analysis via atom-level attribution maps
|
| 88 |
+
- Research on GNN-based molecular property prediction
|
| 89 |
+
|
| 90 |
+
## How to Use
|
| 91 |
+
|
| 92 |
+
```python
|
| 93 |
+
import torch
|
| 94 |
+
from huggingface_hub import hf_hub_download
|
| 95 |
+
|
| 96 |
+
# Load model from HuggingFace
|
| 97 |
+
model_path = hf_hub_download(repo_id="vgoradia/MolScreen", filename="molscreen_best.pt")
|
| 98 |
+
model = torch.load(model_path, map_location='cpu')
|
| 99 |
+
model.eval()
|
| 100 |
+
|
| 101 |
+
# Or try the live Streamlit app — no code needed
|
| 102 |
+
```
|
| 103 |
+
|
| 104 |
+
## Live Demo
|
| 105 |
+
|
| 106 |
+
Try the interactive app (draw a molecule, get toxicity predictions + atom attribution):
|
| 107 |
+
[MolScreen Streamlit App](https://mol-screen-32jrti5gpuajmd8wse5u3f.streamlit.app)
|
| 108 |
+
|
| 109 |
+
## Publications & Acceptances
|
| 110 |
+
|
| 111 |
+
- **NeurIPS 2026 AIDaR Workshop** — ACCEPTED (poster, Paris, December 12 2026)
|
| 112 |
+
- **BIBM 2026 AIPBDA Workshop** — SUBMITTED (Paper ID S49203)
|
| 113 |
+
- **Harvard HSRC 2026** — ACCEPTED (virtual, October 17-18 2026)
|
| 114 |
+
- **Regeneron STS 2027** — SUBMITTED (November 2026)
|
| 115 |
+
- AAAI-27 AISI Track — Submitted (Submission #598)
|
| 116 |
+
|
| 117 |
+
## GitHub
|
| 118 |
+
|
| 119 |
+
[github.com/vgoradia/mol-screen](https://github.com/vgoradia/mol-screen)
|
| 120 |
|
| 121 |
+
## Citation
|
| 122 |
|
| 123 |
+
@misc{goradia2026molscreen,
|
| 124 |
+
title={MolScreen: Interpretable Multi-Task Molecular Toxicity Screening
|
| 125 |
+
with Graph Neural Networks and LLM Triage},
|
| 126 |
+
author={Goradia, Veer},
|
| 127 |
+
year={2026},
|
| 128 |
+
note={NeurIPS 2026 AIDaR Workshop}
|
| 129 |
+
}
|
| 130 |
|
| 131 |
+
## License
|
|
|
|
| 132 |
|
| 133 |
+
Apache 2.0
|
| 134 |
|
| 135 |
+
## Contact
|
| 136 |
|
| 137 |
+
Veer Goradia · vgoradia07@gmail.com
|
|
|